🔗 Share this article

As the US undertakes unprecedented changes to its vaccine guidelines, a particular individual appears unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the global health crisis and has focused upon alleged fatalities following COVID-19 immunization in her brief position at the Food and Drug Administration.

Planned Changes to Childhood Vaccine Program

Public health authorities were set to unveil sweeping changes to the pediatric immunization program recently, bringing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of step with much of the international standard with insufficient data for benefit. This reveal has been pushed back until the next year.

Rather than the director of the vaccine center, Dr. Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing specific childhood immunization guidelines in the US in order to be more similar to the Danish model, a country with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

So far comments, she has kept her attention on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

The appointee has no apparent track record in pharmaceutical research, approval processes or management, which has been typical for previous directors of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of drug development”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that former directors who ran the center have had.”

This division has an immense range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars division, OTC medication office and other areas, and all of those have to be supervised,” Dr. Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major leadership aspect to the position, which supervises more than 5,000 staff members. “It is a massive management job, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Controversial Policies

In response to questions about Høeg’s fitness for the role and whether this appointment represents more teamwork among agency officials on vaccines, a press secretary stated that the “inquiries are based on incorrect premises”.

“This background is consistent with the duties of her job,” the official said, citing the months Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a contentious one-day therapy clearance system that apparently worried her preceding directors. “How are these drugs being selected for this expedited pathway? Who is making the decisions?” Howard said. “There’s a lot of confidentiality going on at the agency right now.”

In general, he said, “the agency appears to be shifting towards less stringent oversight of most medications, aside from immunizations.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, track record, Howard have noted. She published a research paper using non-validated crowd-sourced reports to determine the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the current government included altering rules for new vaccines and halting “optional” vaccines, she remarked following the vote on a audio program. At the agency, Høeg has according to sources suggested preventing adolescent males from getting Covid vaccines.

“She is an all-around ideologue who starts off with her conclusions and tailors the evidence to retrofit the science in a highly deceptive, dishonest fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|